三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
舒沃替尼单药对三代EGFR-TKIs耐药患者显示出疗效信号
舒沃替尼单药对三代EGFR-TKIs耐药患者显示出疗效信号
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:935KB
图片尺寸:1830*1000
同报告图片
/
4
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
5aW955qE77yM5Lul5LiL5piv5oKo5Zu+54mH5Lit55qE5pWw5o2u6KGo5qC85ZKM6LWE5paZ5p2l5rqQ77yaCgp8IOWFrOWPuCB8IOiNr+eJqSB8IOa1t+WkluS4tOW6iumYtuautSB8IOS4reWbveS4tOW6iumYtuautSB8IOWbveWGhemmluasoeWFrOekuuaXtumXtCB8IOWJgumHjyB8IE9SUiB8IOaVsOaNruWfuuS6juS6uuaVsCB8IOWPkeihqOaXtumXtCB8CnwtLS0tLS18LS0tLS0tfC0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS18LS0tLS0tfC0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18Cnwg5by655SfIHwgQW1pdmFudGFtYWIgfCBJSUnvvIjlt7LkuIrluILvvIkgfCAqIHwgMjAyMC4xMi44IHwgPDgwa2fkuLoxMDUwbWfvvIziiaU4MGtn5Li6MTQwMG1nIHwgNDAlIHwgMzYyIHwgMjAyMFdDTEMgfAp8IOatpueUsCB8IE1vYm9jZXJ0aW5pYiB8IElJSe+8iOW3suS4iuW4gu+8iSB8IOW3suS4iuW4giB8IDIwMTkuNC45IHwgMTYwbWcvcWQgfCAyOCUgfCAxMTQgfCAyMDIxQVNDTyB8Cnwg6L+q5ZOy5Yy76I2vIHwg6IiS5rKD5pu/5bC8IHwgSUkgfCAgfCAyMDIxLjUuMTIgfCAzMDBtZy9xZCB8IDU5LjglIHwgOTcgfCAyMDIyRVNNTyB8CnwgU3BlY3RydW0gUGhhcm1hY2V1dGljYWxzIHwg5rOi5aWH5pu/5bC8IHwgSUkgfCDlt7LkuK3mraIgfCAgfCAxNm1nL3FkIHwgMzIlIHwgNTAgfCAyMDIyIENhbmNlciBDZWxsIOacn+WIiiB8CnwgQ3VsbGluYW5PbmNvbG9neS/lho3pvI7ljLvoja8gfCBDTE4tMDgxIHwgSS9JSWEgfCBJSS9JSWEgfCAyMDIxLjcuMjMgfCAxMDBtZy9iaWQgfCA0MSUgfCAzOSB8IDIwMjJBU0NPIHwKfCDoib7lipvmlq8gfCDkvI/nvo7mm7/lsLwgfCBJSSB8ICB8IDIwMjIuNi44IHwgMjQwbWcvcWQgfCA2MCUgfCAxMCB8IDIwMjFFU01PIHwKfCDlv4XotJ3nibnljLvoja8gfCBCRUJULTEwOSB8IElJIHwgIHwgMjAyMC4xLjEzIHwgMTIw44CBMTgw44CBMjQwbWcvcWQgfCBEQ1I9MTAwJSB8IDE5IHwgMjAyMuaLm+iCoeS5piB8Cnwg5ZCb5a6e55Sf54mpL+W+ruWig+eUn+eJqSB8IEFQTC0xODk4IHwgSUkgfCAgfCAyMDIxLjEyLjMxIHwgIHwgIHwgIHwgIHwKfCDnpo/msoPoja/kuJogfCBGV0QxNTA5IHwgSSB8ICB8IDIwMjEuNy4yMyB8ICB8ICB8ICB8ICB8Cnwg57+w5qOu5Yi26I2vIHwgSFMtMTAzNzYgfCBJIHwgIHwgMjAyMS4xMC4xMSB8ICB8ICB8ICB8ICB8Cnwg5Lit5Zu95Yy76I2v56CU56m25byA5Y+R5Lit5b+D5pyJ6ZmQ5YWs5Y+4IHwgTklQMTQyIHwgSSB8ICB8IDIwMjIuNC4xMyB8ICB8ICB8ICB8ICB8CgrotYTmlpnmnaXmupDvvJppbnNpZ2h05pWw5o2u5bqT77yM5ZCE5YWs5Y+45a6Y572R77yM5b+F6LSd54m55Yy76I2v5oub6IKh6K+05piO5Lmm77yM5Lit5L+h6K+B5Yi456CU56m26YOo77yI5rOo77yaQW1pdmFudGFtYWLlnKjlm73lhoXnmoRJSeacn+S4tOW6iumAguW6lOeXh+aYr+iBlOWQiOesrOS4iQ==
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
所属报告:
迪哲医药-公司投资价值分析报告:转化医学平台领先引领中国源头创新走向世界的biotech-230518(47页).pdf
打包全文图表
相关数据
SHR-A2009用于EGFR突变型NSCLC的1期临床研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
Ph2a临床研究Sefaxersen尿蛋白及eGFR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph3NeflgArd研究第24个月eGFR及uPCR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph1/2ADU-CL-19研究中Zigakibart组受试者100周uPCR及eGFR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph1/2aRUBY-3研究中Povetacicept80mg剂量组第48周uPCR及eGFR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
图3 mCRC中EGFR抑制剂的美国收入(2004-2017)
收藏
行业数据
2026-02-13
原图定位
查看详情
三代EGFR药物适应症对比(2025年新增两款)
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
收藏
行业数据
2026-02-04
原图定位
查看详情
第二代EGFR-TKI不同企业竞争格局
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
收藏
竞争格局
2026-01-08
原图定位
查看详情
第一代EGFR-TKI不同企业竞争格局
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
收藏
竞争格局
2026-01-08
原图定位
查看详情
Iza-bren已开展临床研究的癌种(左图中以红字标明)以及EGFR和HER3在各种上皮肿瘤中的
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
收藏
行业数据
2025-12-26
原图定位
查看详情
EGFR/HER3ADC全球格局
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
收藏
竞争格局
2025-12-26
原图定位
查看详情
图表20EGFR耐药后NSCLC试验数据比
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
收藏
行业数据
2025-12-03
原图定位
查看详情
和誉ABSK043的临床定位以及未来结合EGFR/KRAS等小分子抑制剂在NSCLC中布局的管线矩阵
fCDkurrnvqQgICB8IEVHRlJtdXQgfCBLUkFTbXV0IHwKfC0tLS0tLS0tfC0tLS0tLS0tLXwtLS0tLS0tLS18Cnwg6KW/5pa55Lq6576kIHwgMjAlICAgICB8IDI1JSAgICAgfAp8IOS6mua0suS6uue+pCB8IDUwJSAgICAgfCAxMCUgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuFBQVA==
收藏
行业数据
2025-10-10
原图定位
查看详情
EGFR突变NSCLC患者推荐用药(CSCO及NCCN指南)
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
收藏
行业数据
2025-09-23
原图定位
查看详情
截至2025年9月,全球共6款EGFR单抗ADC药物进入临床
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
收藏
行业数据
2025-09-23
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
舒沃替尼对多种 EGFR 突变均有效,单药治疗对 EGFR-TKIs 耐药患者显示出疗效信号。根据公司招股说明书,舒沃替尼对所有已知的 EGFR 和 HER2 突变都有很好的药效,包括对所有已批准的 EGFR 药物的靶点突变(Del19、L858R、T790M)以及非常规突变G719S、L861Q 等。因此舒沃替尼对于三代 EGFR-TKIs 治疗后发生的 EGFR 通路继发性耐药仍然具有一定疗效。截至 2022 年 7 月 31 日,共 29 例携带 EGFR 敏感突变或 EGFR敏感突变合并 T790M 耐药突变的受试者纳入合并分析,既往中位治疗线数为 5 线,共 6名受试者实现了 PR(ORR=20.7%),mPFS 为 5.9 个月,显示出舒沃替尼对 EGFR-TKIs耐药患者显示出疗效信号。
行业数据
原图定位
当前图表所属:
迪哲医药-公司投资价值分析报告:转化医学平台领先引领中国源头创新走向世界的biotech-230518(47页).pdf
表6资料来源),研究分析了三家医院EGFR20ins患者53例(占NSCLC患者的2.4%),
舒沃替尼与竞品药物的疗效和安全性比较
国内正在进行的ex20ins适应症临床试验及临床数据
现有三代EGFR抑制剂的获批适应症
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》